This is how much £1K invested in GSK shares 5 years ago would be worth today

GlaxoSmithKline plc (LON: GSK) is a popular stock. But has it been a good investment?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) is a very popular stock among UK investors. Along with other well-known FTSE 100 names, such as Lloyds Bank, BP, and Royal Dutch Shell, the pharmaceutical giant can be found within a lot of private investor portfolios.

Have GSK shares been a good investment over the last five years though? Let’s take a look at the stock’s five-year return.

GSK has smashed the FTSE 100

On 18 December 2014, GSK shares traded between 1,316p and 1,361p. Had you paid the average of these two prices and picked up some shares at 1,339p, an investment of £1,000 would have got you 74 shares (the cost would have been £991 plus trading commissions).

Now, over the last five years, Glaxo shares have had their ups and downs. So, had you purchased five years ago, there would have been a few occasions where you were sitting on unrealised capital losses. For example, in September 2015, the stock fell to near 1,200p. 

Today, however, GSK’s share price stands at 1,796p meaning those 74 shares would now be worth around £1,329. That equates to a capital gain of around 34% (or 6.1% on an annualised basis) which is certainly not a bad result.

By contrast, the FTSE 100 has produced a capital gain of approximately 18% (3.3% per year) over that time period. So, from a capital gain perspective, GSK shares have easily beaten the market.

Dividends have turbocharged returns

Of course, when you add dividends into the equation, GSK’s returns have been much higher. Glaxo has paid a large dividend over the last five years and this has had a powerful impact on investor returns.

Looking at GSK’s dividend history, had you purchased the stock on 18 December 2014, you would have picked up dividends of 382p per share so far. As such, a holding of 74 shares would have generated dividends of £283.

If we add this figure to the value of the shares (which assumes you didn’t reinvest your dividends), the total comes to £1,612.

So, overall, had you invested £1,000 in GSK shares five years ago, your money would now be worth £1,612 (not counting trading commissions). That equates to a total gain of 62.7% over five years or 10.2% on an annualised basis. I see that as a pretty decent return – if you earn 10%+ on your money every year, you’ll become wealthy pretty quickly.

Two key takeaways 

To my mind, there are a couple of key takeaways from this GSK analysis. 

Firstly, rewards come to those who are patient. GSK shares have had their ups and downs over the last five years. Those who have stuck it out have made good money. 

Secondly, dividends really can have a huge impact on stock market investment returns. Excluding dividends, GSK shares returned just over 6% per year. However, when you include dividends, the stock generated a return of more than 10% per year, which is an excellent return.

All too often, investors ignore dividends when investing in shares because they see them as negligible. Dividends shouldn’t be underestimated though. Over time, they can be an extremely powerful wealth creation tool.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline, Lloyds Bank and Royal Dutch Shell. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

This S&P 500 stock just hit $1 trillion! Which one will be next?

This often-overlooked semiconductor business just surpassed a $1trn market capitalisation as demand for its AI chips explodes to record highs!

Read more »

Investing Articles

Down 70% with a P/E of 3.5! Is this FTSE 250 stock on the verge of a MASSIVE comeback?

Motor finance lenders are getting a second chance in court that could avoid £30bn in penalties. Is this FTSE 250…

Read more »

Investing Articles

This FTSE 100 stock’s down 50% with a forward P/E of just 6.6! Is it a screaming buy for me?

This FTSE 100 homebuilder surged 40% during most of 2024 before crashing, creating what looks like a lucrative buying opportunity.…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Is Nvidia heading for the mother of all stock crashes in 2025?

After a seemingly unstoppable rise, is AI chipmaker Nvidia's stock going to suffer badly if the current AI boom cools…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Fancy a 13.9% dividend yield? Consider these dirt-cheap investment trusts!

These investment trusts are trading at whopping discounts to their net asset values (NAVs). Here's why they could prove to…

Read more »

Investing Articles

If the market shut down for 10 years, I’d be happy to hold these 2 FTSE 100 shares

Our writer reveals a pair of FTSE 100 shares that he reckons are well set up to deliver strong returns…

Read more »

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »